Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Lonely Bacteria are More Likely to Become Antibiotic-resistant

Published: Wednesday, April 30, 2014
Last Updated: Wednesday, April 30, 2014
Bookmark and Share
Scientists from the University of Manchester have discovered that microbes in smaller groups are more likely to mutate, resulting in higher rates of antibiotic resistance.

The study, published today in ‘Nature Communications’ and jointly funded by the Wellcome Trust and the Engineering and Physical Sciences Research Council, explored mutation rates in E. coli bacteria.

The researchers found out that the rate of mutation varied according to how many of the bacteria there were. Surprisingly, they discovered that larger groups of bacteria were less likely to mutate than smaller groups.

The more ‘lonely’ bacteria mutated more, and developed greater resistance to the well-known antibiotic Rifampicin, used to treat tuberculosis.

Dr Chris Knight, joint lead author on the study with Dr Rok Krašovec, from the University of Manchester, said: “What we were looking for was a connection between the environment and the ability of bacteria to develop the resistance to antibiotics. We discovered that the rate at which E. coli mutates depends upon how many ‘friends’ it has around. It seems that more lonely organisms are more likely to mutate.”

This change of the mutation rate is controlled by a form of social communication known as quorum sensing – this is the way bacteria let each other know how much of a crowd there is. Quorum sensing involves the release of signalling molecules by bacteria: the denser the population, the more of these molecules released and detected. This helps the bacteria understand their environment and coordinate their behaviour to improve their defence mechanisms and adapt to the availability of nutrients.

Dr Krašovec said: “We were able to change their mutation rates by changing who they shared a test-tube with, which could mean that bacteria manipulate each other’s mutation rates. It also suggests that mutation rates could be affected when bacteria are put at low densities, for instance by a person taking antibiotics.”

The rate of mutation was found to depend on the gene luxS, which is known to be involved in quorum sensing in a wide range of bacteria.

The team now hopes to find ways to control this signalling for medical applications in a future study funded by the Biotechnology and Biological Sciences Research Council.

“Eventually this might lead to interventions to control mutation rates, for instance to minimise the evolution of antibiotic resistance, allowing antibiotics to work better,” said Dr Knight.

Dr Mike Turner, Head of Infection and Immunobiology at the Wellcome Trust, said: “Antibiotic resistance is a real threat to disease control and public health today. Any insight into the origins of such resistance is valuable in the fight to prevent it. Chris Knight and his team have gained a fundamental understanding of bacterial communication and the development of mutations which in the long run could contribute to more potent antibiotics and better control of bacterial disease”.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Data from Historic Phase IIb Clinical Trial for Tuberculosis Vaccine Candidate Published
Vaccine candidate did not provide statistically-significant protection in preventing TB disease in infants previously vaccinated with BCG.
Monday, February 04, 2013
Scientific News
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Structure of Crucial Enzyme Identified
Researchers at UTSW have determined the atomic structure of an enzyme that plays an essential role in cell division and better treatment of cancer.
New Immunotherapy Trial for Type 1 Diabetes
The search for a treatment for Type 1 diabetes (T1D) - which affects over 400,000 people in the UK – will be stepped up with the start of a new phase one clinical trial at Guy’s Hospital in London.
Recruitment of First Patient in Clinical Study
Company has announced recruitment of first patient in clinical study assessing Visco-ease with Beatson Cancer Centre for the treatment of RIX.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!